Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 131 HARTWELL AVENUE, SUITE 320 LEXINGTON MA 02421 |
Tel: | 1-917-6182651 |
Website: | https://www.aldeyra.com |
IR: | See website |
Key People | ||
Todd C. Brady President, Chief Executive Officer, Director | Bruce Greenberg Senior Vice President - Finance, Interim Chief Financial Officer | Stephen Machatha Chief Development Officer |
Business Overview |
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases. |
Financial Overview |
For the fiscal year ended 31 December 2023, Aldeyra Therapeutics Inc revenues was not reported. Net loss decreased 39% to $37.5M. Lower net loss reflects Research and development decrease of 39% to $26.4M (expense), Interest income increase from $2.3M to $7.3M (income), General and administrative expenses decrease of 36% to $2.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.06 to -$0.64. |
Employees: | 10 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $103.78M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$42.53M as of Dec 31, 2023 |
Net annual income (TTM): | -$37.54M as of Dec 31, 2023 |
Free cash flow (TTM): | -$30.33M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 58,895,768 as of Mar 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |